Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Mineralys Therapeutics (MLYS) will participate in the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026.

Management's fireside chat is scheduled for 12:00 p.m. ET. A live webcast will be available on the “News & Events” page in the Investor Relations section of the company's website.

Argus Sep 25 session 17 alerts

-2.75% close to close 0.9x rel. volume Open Argus

Details

News Market Reaction – MLYS

$2.26B Mkt Cap at Peak Alert

On Sep 25, the first trading day after this news, MLYS closed 2.75% below the previous close. Our momentum scanner recorded 17 alerts for this stock that day.

Data tracked by StockTitan Argus for the Sep 25 session.

Key Terms

aldosterone

1 terms

aldosterone medical

"medicines to target hypertension and aldosterone-related adverse outcomes"

Aldosterone is a hormone made by small glands above the kidneys that helps the body hold on to salt and water and release potassium, functioning like a household thermostat that adjusts fluid levels. It matters to investors because drugs or tests that change or measure aldosterone can alter treatment of high blood pressure, heart failure and kidney disease, affecting sales, trial outcomes and regulatory decisions in related healthcare markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

09/24/2026 - 04:05 PM EDT

RADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Stifel 2026 Virtual Cardiometabolic Forum taking place on September 30, 2026.

Stifel 2026 Virtual Cardiometabolic Forum
Date:		Wednesday, September 30, 2026
Time:		12:00pm ET
Format:		Fireside Chat

A live webcast of this fireside chat can be accessed on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.

About Mineralys Therapeutics
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.

Contact:

Investor Relations investorrelations@mineralystx.com